CDKN1A and glioblastoma: Knocking down FAK with CRISPR Cas9 caused an upregulation of p21/p27 cell-cycle inhibitors, strong growth inhibition in cultured GBM cells, and sustained antitumorigenic effects in orthotopic GBM xenografts in vivo.